Mr. Zeeshan Saeed reports

HEALTH CANADA GRANTS QUANTUM BIOPHARMA A PRODUCT LICENSE FOR ITS INNOVATIVE PRODUCT, QLARITY(TM), THAT ENHANCES ENERGY, AND PROMOTES METABOLISM, MENTAL ALERTNESS AND COGNITIVE PERFORMANCE

Quantum Biopharma Ltd.'s chief regulator, Health Canada, has granted a product licence (PN 80144141) for its natural health product, Qlarity. Quantum licensed a similar product, as a dietary supplement, for sale in the United States under the brand name unbuzzd. This product licence from Health Canada permits Quantum to sell Qlarity in Canada.

Health Canada's product licence permits the following recommended uses of Qlarity, among others: helps in energy production and metabolism; helps to maintain/support normal electrolyte balance; helps (temporarily) to enhance (physical) energy and motor performance, reduce fatigue, promote endurance, promote mental alertness, and enhance cognitive performance.

"This is a milestone in Quantum Biopharma's mission to bring innovative products to the market," said Zeeshan Saeed, chief executive officer of Quantum Biopharma. "We can now sell Qlarity to the Canadian market, leveraging its significant potential to improve consumer well-being."

"I am delighted that the Natural Health Products Directorate at Health Canada has provided a product licence for Qlarity", said Professor Lakshmi P. Kotra, a board director at Quantum Biopharma, a professor of medicinal chemistry at University of Toronto and a senior scientist at the Krembil Research Institute, University Health Network. "I look forward to the launch of Qlarity in Canada, offering a solution to support energy, metabolism, mental alertness and cognitive performance."

About Quantum Biopharma Ltd.

Quantum Biopharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development.

We seek Safe Harbor.